Skip to Main Content

Paper Details

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
JAMA
523
2008
VTE, Venous thromboembolism, anemia, cancer, cancer-associated anemia, chemotherapy, darbepoetin, erythropoietin, erythropoietin receptors, nonmyeloid malignancies, recombinant erythropoietin, solid cancers, venous thromboembolism
Anemia, Clinical Trials, Phase III as Topic, Darbepoetin alfa, Erythropoietin, Hematinics, Humans, Neoplasms, Recombinant Proteins, Risk, Survival Rate, Venous Thromboembolism
Author NameAffiliation
Charles L BennettVA Chicago Healthcare System, Northwestern University Feinberg School of Medicine, and Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Charles L BennettVA Chicago Healthcare System, Northwestern University Feinberg School of Medicine, and Robert H. Lurie Comprehensive Cancer Center, Northwestern University
  • 1 - 2

Datasets

Release 1.2